PR Newswire - T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 ...
BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical st...
Read More


ภาษาไทย
English